Speedy review for pioneering drugs: understanding Japan's new Sakigake process
This article was originally published in SRA
Executive Summary
Sakigake is becoming an increasingly familiar buzzword in Japan and beyond following the first unveiling of the proposals by the country's drugs and devices regulator, the PMDA, around the middle of last year1.
You may also be interested in...
Oncology Dominates Japan Approvals, Though Overall Tally Is Lower
Although it approved fewer new products last fiscal year, Japan granted access to a number of important new therapies, including in oncology and several for the first time worldwide, helped by continuing reforms at its regulatory body.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Teva’s immunology biosimilar launches; Intra-Cellular’s promising depression data; Phase III sleep apnea win for Lilly’s tirzepatide; an interview with Viking’s CEO; and China looks to define innovative drugs.